Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Joensuu, H., Sailas, L., Alanko, T., Sunela, K., Huuhtanen, R., Utriainen, M., Kokko, R., Bono, P., Wigren, T., Pyrhönen, S., Turpeenniemi-Hujanen, T., Asola, R., Leinonen, M., Hahka-Kemppinen, M., Kellokumpu-Lehtinen, P.
Published in Annals of oncology (01.05.2010)
Published in Annals of oncology (01.05.2010)
Get full text
Journal Article
Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation
Vartia, Aarne, Asola, Markku R., Tertti, Risto, Kunelius, Pertti, Metsärinne, Kaj P.
Published in Nephrology, dialysis, transplantation (01.05.2004)
Published in Nephrology, dialysis, transplantation (01.05.2004)
Get full text
Journal Article
Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial
Bono, P., Kellokumpu-Lehtinen, P.-L., Alanko, T., Kokko, R., Asola, R., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Kataja, V., Leinonen, M., Joensuu, H.
Published in Annals of oncology (01.03.2009)
Published in Annals of oncology (01.03.2009)
Get full text
Journal Article
S24 Update of the FINHER trial based on 5 years of follow-up
Joensuu, H, Bono, P, Kataja, V, Alanko, T, Kokko, R, Asola, R, Utriainen, T, Turpeenniemi-Hujanen, T, Isola, J, KellokumpuLehtinen, P
Published in Breast (Edinburgh) (2009)
Published in Breast (Edinburgh) (2009)
Get full text
Journal Article
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study
Salminen, E, Korpela, J, Varpula, M, Asola, R, Varjo, P, Pyrhönen, S, Mali, P, Hinkka, S, Ekholm, E
Published in Anti-cancer drugs (01.10.2002)
Published in Anti-cancer drugs (01.10.2002)
Get more information
Journal Article
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Bono, Petri, Alanko, Tuomo, Kataja, Vesa, Asola, Raija, Utriainen, Tapio, Kokko, Riitta, Hemminki, Akseli, Tarkkanen, Maija, Turpeenniemi-Hujanen, Taina, Jyrkkiö, Sirkku, Flander, Martti, Helle, Leena, Ingalsuo, Seija, Johansson, Kaisu, Jääskeläinen, Anna-Stina, Pajunen, Marjo, Rauhala, Mervi, Kaleva-Kerola, Jaana, Salminen, Tapio, Leinonen, Mika, Elomaa, Inkeri, Isola, Jorma
Published in The New England journal of medicine (23.02.2006)
Published in The New England journal of medicine (23.02.2006)
Get full text
Journal Article
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Kellokumpu-Lehtinen, Pirkko-Liisa, Prof, Harmenberg, Ulrika, MD, Joensuu, Timo, MD, McDermott, Ray, MD, Hervonen, Petteri, MD, Ginman, Claes, MD, Luukkaa, Marjaana, MD, Nyandoto, Paul, MD, Hemminki, Akseli, Prof, Nilsson, Sten, Prof, McCaffrey, John, Prof, Asola, Raija, MD, Turpeenniemi-Hujanen, Taina, Prof, Laestadius, Fredrik, MD, Tasmuth, Tiina, MD, Sandberg, Katinka, MD, Keane, Maccon, MD, Lehtinen, Ilari, BSc, Luukkaala, Tiina, MSc, Joensuu, Heikki, Prof
Published in The lancet oncology (01.02.2013)
Published in The lancet oncology (01.02.2013)
Get full text
Journal Article
4019 POSTER Phase III, randomized, open-label study of triweekly docetaxel (tT) vs. biweekly docetaxel (bT) as treatment for advanced hormone refractory prostate cancer (HRPC): findings from an interim safety analysis
Kellokumpu-Lehtinen, P, Joensuu, T, Hervonen, P, Nyandoto, P, Luukkaala, T, Hemminki, A, Asola, R, Luukkaa, M, Lehtinen, I, Joensuu, H
Published in European journal of cancer supplements (2007)
Published in European journal of cancer supplements (2007)
Get full text
Journal Article
Amino acid uptake in the skeletal muscle measured using [11C]methylaminoisobutyrate (MEAIB) and PET
ASOLA, Markku R, VIRTANEN, Kirsi A, PELTONIEMI, Pauliina, NAGREN, Kjell, MEIXIANG YU, MATTILA, Kari, JYRKKIÖ, Sirkku, METSÄRINNE, Kaj, NUUTILA, Pirjo, KNUUTI, Juhani
Published in European journal of nuclear medicine and molecular imaging (01.11.2002)
Published in European journal of nuclear medicine and molecular imaging (01.11.2002)
Get full text
Journal Article
Phase III, randomized, open-label study of triweekly docetaxel versus biweekly docetaxel as treatments for advanced hormone-refractory prostate cancer: Findings from an interim safety analysis of the Finnish Uro-oncological Group Study 1-2003
Hervonen, P., Joensuu, H., Joensuu, T. K., Nyandoto, P., Luukkaa, M., Nilsson, S., Hemminki, A. E., Asola, R., Luukkaala, T., Kellokumpu-Lehtinen, P.
Published in Journal of clinical oncology (01.03.2011)
Published in Journal of clinical oncology (01.03.2011)
Get full text
Journal Article
Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis
Kellokumpu-Lehtinen, Pirkko-Liisa Irmeli, Harmenberg, Ulrika, Hervonen, Petteri, Joensuu, Timo K., McDermott, Raymond S., Ginman, Claes, Luukkaa, Marjaana, Nyandoto, Paul, Hemminki, Akseli, Nilsson, Sten, McCaffrey, John, Asola, Raija, Turpeenniemi Hujanen, Taina, Laestadius, Fredrik, Tasmuth, Tiina, Sandberg, Katinka, Keane, Maccon M., Lehtinen, Ilari, Luukkaala, Tiina, Joensuu, Heikki
Published in JOURNAL OF CLINICAL ONCOLOGY (01.02.2014)
Published in JOURNAL OF CLINICAL ONCOLOGY (01.02.2014)
Get full text
Journal Article
Conference Proceeding
Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial
Joensuu, H, Kellokumpu-Lehtinen, P, Huovinen, R, Jukkola-Vuorinen, A, Asola, R, Kokko, R, Ahlgren, J, Bono, P, Tanner, M, Lindman, H, Group, for The Finnish Breast Cancer
Published in Cancer research (Chicago, Ill.) (15.01.2009)
Published in Cancer research (Chicago, Ill.) (15.01.2009)
Get full text
Journal Article
Docetaxel 100 versus 80 mg/m[sup]2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial
Bono, P, P.-l. Kellokumpu-lehtinen, Alanko, T, Kokko, R, Asola, R, Turpeenniemi-hujanen, T, Jyrkkiö, S, Kataja, V, Leinonen, M, Joensuu, H
Published in Annals of oncology (01.03.2009)
Published in Annals of oncology (01.03.2009)
Get full text
Journal Article
The FinXX trial: Safety results in 600 patients (pts) randomized to either docetaxel (T) followed by cyclophosphamide (C) + epirubicin (E) + 5-FU (F) (CEF) or T + capecitabine (X) followed by CEX as adjuvant therapy for early breast cancer (BC)
Joensuu, H., Hemminki, A., Huovinen, R., Tanner, M., Kokko, R., Asola, R., Jukkola-Vuorinen, A., Lahtela, S., Lindman, H., Kellokumpu-Lehtinen, P.
Published in Journal of clinical oncology (20.06.2007)
Published in Journal of clinical oncology (20.06.2007)
Get full text
Journal Article